Kidney Disease Treatment (CKD) — Cost, Top Hospitals & Success Rates | MyMedicPlus

Chronic kidney disease (CKD) is defined by the Kidney Disease: Improving Global Outcomes (KDIGO) consortium as the presence of abnormalities of kidney structure or function — evidenced by a glomerular filtration rate (GFR) below 60 mL/min/1.73 m², or kidney damage markers (proteinuria, haematuria, imaging or biopsy abnormalities) — that persist for more than three months and have implications for health. CKD affects an estimated 850 million people worldwide, representing approximately 10–15% of adults globally, and is a leading cause of premature cardiovascular death.

The treatment landscape for CKD has been transformed in the early 2020s by breakthrough clinical trial evidence. The 2024 KDIGO Clinical Practice Guideline for CKD incorporates landmark data from the DAPA-CKD trial (dapagliflozin), EMPA-KIDNEY trial (empagliflozin), FIDELIO-DKD and FIGARO-DKD trials (finerenone), FLOW trial (semaglutide), and SPRINT trial (intensive blood pressure control). Together, these trials establish a new four-pillar pharmacological foundation for CKD management that dramatically reduces the risk of kidney disease progression and major adverse cardiovascular events (MACE).

The overarching goals of CKD treatment are: (1) to identify and treat the underlying cause of CKD where possible; (2) to slow or halt the rate of GFR decline; (3) to prevent and manage cardiovascular disease — the leading cause of death in CKD; (4) to detect, prevent, and treat CKD complications including anaemia, mineral bone disease (MBD), metabolic acidosis, hyperkalaemia, and malnutrition; and (5) to prepare patients with progressive CKD (stages G4–G5) for renal replacement therapy (RRT) or conservative kidney management (CKM), with timely and shared decision-making.

This guide synthesises current KDIGO 2024 recommendations, major trial evidence, and practical clinical management for patients, carers, and healthcare professionals navigating CKD treatment decisions.

The KDIGO CGA (Cause-GFR-Albuminuria) staging system provides the framework for risk stratification, treatment intensity, and monitoring frequency in CKD.

GFR Staging (G1–G5)

• G1: GFR ≥90 mL/min/1.73 m² — Normal or high GFR with other markers of kidney damage (proteinuria, haematuria). Often asymptomatic. Focus on treating underlying cause and risk factor control.
• G2: GFR 60–89 — Mildly decreased. Cardiovascular risk assessment and optimisation central to management.
• G3a: GFR 45–59 — Mild to moderately decreased. Begin complication screening (anaemia, MBD, bicarbonate).
• G3b: GFR 30–44 — Moderate to severely decreased. Nephrology referral recommended. Preparation for RRT discussion may begin.
• G4: GFR 15–29 — Severely decreased. Active RRT planning (fistula creation, PD catheter, transplant workup) should be underway.
• G5: GFR <15 — Kidney failure. RRT initiation or CKM decision required.

Albuminuria Staging (A1–A3)

Urine albumin-to-creatinine ratio (UACR) staging refines cardiovascular and kidney risk beyond GFR alone:

• A1: UACR <30 mg/g (normal to mildly increased)
• G2: UACR 30–300 mg/g (moderately increased, formerly 'microalbuminuria')
• A3: UACR >300 mg/g (severely increased, formerly 'macroalbuminuria' or 'overt proteinuria')

The combination of GFR and albuminuria staging (e.g., G3b A3) defines a heat-map of risk for CKD progression and death that guides treatment intensity.

Common Causes of CKD

The three most common causes of CKD globally are diabetic kidney disease (DKD) (approximately 40% of cases), hypertensive nephrosclerosis (25%), and glomerulonephritis (various types, approximately 15%). Other causes include polycystic kidney disease (ADPKD), recurrent pyelonephritis and reflux nephropathy, obstructive uropathy, analgesic nephropathy, renovascular disease, and systemic lupus erythematosus nephritis. Accurate diagnosis of the underlying cause is critical, as cause-specific therapies (immunosuppression for glomerulonephritis, tolvaptan for ADPKD, surgical relief of obstruction) may be available.

The Cardio-Renal-Metabolic Nexus

CKD is not merely a kidney condition. It is now understood as a cardio-renal-metabolic (CRM) syndrome characterised by bidirectional interactions between the kidneys, heart, and metabolic organs. Patients with CKD G3–G5 are 5–10 times more likely to die from cardiovascular causes (myocardial infarction, heart failure, sudden cardiac death) than to reach dialysis. This understanding drives the recommendation to apply cardiovascular risk reduction strategies — particularly SGLT2 inhibitors and finerenone — across the CKD population irrespective of diabetes status.

All patients with confirmed CKD require active management, though the intensity and complexity of treatment scales with GFR stage, albuminuria category, and comorbidity burden.

Primary Care Management (G1–G3a)

Most patients with early CKD (G1–G3a, A1–A2) can be effectively managed by their primary care physician or general internist, with annual nephrology review. Key primary care tasks include: confirming and monitoring CKD staging, optimising blood pressure and glycaemic control, prescribing RAAS blockade and SGLT2 inhibitor if indicated, monitoring for hyperkalaemia and acute kidney injury (AKI), screening for and managing CKD complications, and providing lifestyle and dietary counselling.

Nephrology Referral Criteria (KDIGO 2024)

Referral to a nephrologist is recommended in the following circumstances:

• GFR <30 mL/min/1.73 m² (G4–G5) — for preparation of RRT or CKM
• Rapid decline in GFR (>5 mL/min/1.73 m² per year, or >10 mL/min in 5 years)
• UACR >300 mg/g, particularly if increasing despite RAAS blockade
• Resistant hypertension (>4 antihypertensive agents)
• Complications requiring specialist input: severe anaemia, refractory hyperkalaemia, severe MBD, metabolic acidosis
• Diagnostic uncertainty regarding CKD aetiology — biopsy consideration
• Nephrotic syndrome (UACR >2,200 mg/g, hypoalbuminaemia, oedema)
• Haematuria with proteinuria in a young patient (possible primary glomerulonephritis)

Patient Education and Self-Management

All CKD patients benefit from structured education about their diagnosis, CKD staging, the expected trajectory of their disease, and the role of lifestyle modifications. CKD nurse specialist or pharmacist-led CKD clinics have demonstrated improved adherence, earlier nephrology referral, and better metabolic control in integrated CKD care programmes.

The 2024 KDIGO guideline establishes a multi-drug, risk-stratified approach to CKD treatment centred on four synergistic pillars of kidney and cardiovascular protection.

Pillar 1: RAAS Blockade (ACE Inhibitors and ARBs)

Angiotensin-converting enzyme inhibitors (ACEi) such as ramipril, lisinopril, and perindopril, and angiotensin II receptor blockers (ARBs) such as losartan, irbesartan, and candesartan, remain foundational for CKD patients with albuminuria (A2–A3). The RENAAL and IDNT trials established ARBs as reducing ESKD risk by 28–32% in diabetic nephropathy. RAAS blockers lower intraglomerular pressure, reduce proteinuria, and slow GFR decline. They should be used to the maximum tolerated dose in all CKD patients with UACR >30 mg/g. Combination ACEi + ARB is not recommended due to increased AKI and hyperkalaemia risk without additional benefit (ONTARGET trial).

Pillar 2: SGLT2 Inhibitors

Sodium-glucose cotransporter-2 (SGLT2) inhibitors represent the most significant advance in CKD treatment in decades. The DAPA-CKD trial (2020, NEJM) demonstrated that dapagliflozin (10 mg daily) reduced the composite of sustained 50% GFR decline, ESKD, or kidney/cardiovascular death by 39% in CKD patients (both diabetic and non-diabetic, GFR 25–75 with UACR >200). The EMPA-KIDNEY trial (2022, NEJM) showed empagliflozin (10 mg daily) reduced kidney disease progression or cardiovascular death by 28% across a broad CKD population including GFR 20–45. KDIGO 2024 gives a strong Grade 1A recommendation for SGLT2 inhibitors in all CKD patients with type 2 diabetes and GFR ≥20 with UACR ≥200, and a conditional Grade 2A recommendation for non-diabetic CKD with UACR ≥200. Key mechanisms include haemodynamic (tubuloglomerular feedback restoration, intraglomerular pressure reduction), metabolic, and anti-fibrotic effects independent of glucose lowering.

Pillar 3: Finerenone (Non-steroidal MRA)

Finerenone is a selective, non-steroidal mineralocorticoid receptor antagonist (MRA) that provides kidney and cardiovascular protection beyond RAAS blockade alone. The FIDELIO-DKD trial (2020, NEJM) and FIGARO-DKD trial (2021, NEJM) together demonstrated that finerenone reduced CKD progression by 15% and major adverse cardiovascular events (MACE) by 13% in patients with diabetic kidney disease on maximum tolerated RAAS blockade. Unlike spironolactone and eplerenone, finerenone carries a lower risk of gynaecomastia and has greater cardiac selectivity. It requires UACR ≥30 mg/g, GFR ≥25, and potassium ≤4.8 mmol/L before initiation, with regular serum potassium monitoring.

Pillar 4: GLP-1 Receptor Agonists

The FLOW trial (2024, NEJM) established semaglutide (1 mg subcutaneous weekly) as a kidney-protective agent in CKD with type 2 diabetes, reducing the composite kidney endpoint by 24% and MACE by 18%. GLP-1 agonists additionally provide substantial weight loss, blood pressure reduction, and cardiovascular benefit relevant to the CKD population with obesity and heart failure.

Blood Pressure Management

Target blood pressure is <120/80 mmHg for most non-dialysis CKD patients, as established by the SPRINT trial and supported by KDIGO 2024, measured using standardised office BP measurement (AOBP). First-line agents are ACEi or ARB; additional agents include amlodipine and thiazide/thiazide-like diuretics. Loop diuretics replace thiazides at GFR <30. Fludrocortisone-sensitive resistant hypertension should prompt screening for primary aldosteronism.

Glycaemic Control in CKD-Diabetes

Target HbA1c in CKD with diabetes is generally 6.5–8.0%, individualised based on hypoglycaemia risk, life expectancy, and dialysis status. SGLT2 inhibitors and GLP-1 agonists are preferred for their dual kidney-cardiovascular benefit. Metformin is safe down to GFR 30 (hold at GFR <30 or during AKI). Sulphonylureas carry high hypoglycaemia risk and should be used cautiously or avoided in advanced CKD.

Anaemia Management

CKD-related anaemia (target Hb 10–12 g/dL) is managed sequentially: first replete iron stores (IV iron preferred over oral iron in CKD G3b–G5 and dialysis — PIVOTAL trial), then initiate erythropoiesis-stimulating agents (ESAs: darbepoetin alfa, epoetin alfa) if Hb remains <10 g/dL after iron optimisation. Avoid ESA hyper-correction above 13 g/dL due to stroke and MACE risk (TREAT trial). Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) such as roxadustat and daprodustat are approved alternatives to ESAs in some countries.

CKD-Mineral Bone Disease (MBD)

Calcium-phosphate disturbance becomes clinically relevant from G3b onwards. Management includes: dietary phosphate restriction, phosphate binders (calcium-based such as calcium carbonate for early stages; non-calcium-based such as sevelamer carbonate, lanthanum carbonate for dialysis patients to avoid vascular calcification), active vitamin D analogues (calcitriol, alfacalcidol) to suppress PTH, and cinacalcet (a calcimimetic) or parathyroidectomy for refractory secondary hyperparathyroidism on dialysis.

Metabolic Acidosis

Target serum bicarbonate ≥22 mmol/L. Oral sodium bicarbonate supplementation slows GFR decline and is recommended when bicarbonate falls below 22 mmol/L (Grade 2B, KDIGO 2024). The Preserve Renal Function trial provides supportive evidence.

Contemporary CKD treatment, when applied comprehensively and early, significantly reduces the risk of both kidney disease progression and premature death. The following summarises the magnitude of benefit from key interventions, based on landmark randomised controlled trial data.

Kidney Protection

• SGLT2 inhibitors: 28–39% relative risk reduction in CKD progression (ESKD, sustained GFR decline ≥50%, kidney death) — the largest single class effect observed in CKD trials
• ACEi/ARBs: 28–32% relative risk reduction in ESKD in diabetic nephropathy (RENAAL, IDNT), with proteinuria reduction of 30–50%
• Finerenone: 15% relative risk reduction in CKD progression on top of maximum RAAS blockade (FIDELIO-DKD)
• GLP-1 agonists: 24% relative risk reduction in kidney progression in CKD-diabetes (FLOW)
• Combined four-pillar therapy: Modelling studies suggest that combining all four pillars in appropriate patients could reduce lifetime ESKD risk by 50–70% compared with RAAS blockade alone

Cardiovascular Protection

CKD patients on optimal medical therapy experience approximately 20–40% reductions in MACE (myocardial infarction, stroke, hospitalisation for heart failure, cardiovascular death) compared with standard care alone. SGLT2 inhibitors are particularly effective at preventing hospitalisations for heart failure. Finerenone reduces MACE by 13%. GLP-1 agonists reduce MACE by 18% in CKD-diabetes. The cardiovascular benefit of CKD treatment is now considered at least as important as — and in early-mid CKD stages, more immediately clinically relevant than — preventing ESKD itself.

Quality of Life

Effective CKD management preserves quality of life by preventing fatigue from anaemia, bone pain from MBD, symptoms of uraemia (nausea, pruritus, cognitive impairment), and cardiovascular events. Early and proactive treatment allows patients with CKD to lead full and active lives, often for decades, without reaching the need for dialysis.

Managing CKD requires careful attention to drug interactions, dose adjustments for reduced GFR, and monitoring for treatment-emergent complications.

ACEi/ARB Risks

RAAS blockers predictably reduce GFR by 10–15% at initiation due to dilation of the efferent glomerular arteriole — this is a haemodynamic adaptation, not true kidney injury, and should not trigger discontinuation unless GFR falls >30% or creatinine rises >30% within 4 weeks. Hyperkalaemia (potassium >5.5 mmol/L) is the principal dose-limiting adverse effect, particularly in GFR <45. Patiromer or sodium zirconium cyclosilicate (SZC) can facilitate continued RAAS blockade in hyperkalaemia. Avoid NSAIDs and nephrotoxic contrast during RAAS blockade (the 'triple whammy' triad increases AKI risk).

SGLT2 Inhibitor Risks

The principal risks of SGLT2 inhibitors relevant to CKD include: genital mycotic infections (particularly in women — 5–10% of cases, managed with topical antifungal treatment); euglycaemic diabetic ketoacidosis (rare, ~0.5/1,000 patient-years — hold peri-operatively and during prolonged fasting); and urinary tract infections (modest increased risk). Volume depletion may require diuretic dose reduction at initiation. SGLT2 inhibitors should be held during acute illness or surgery.

Finerenone Risks

Hyperkalaemia is the principal risk (potassium >5.5 mmol/L occurs in 1.5–2.5% of finerenone-treated patients vs 0.9% with placebo in trials — manageable with dietary potassium restriction and potassium binders). Unlike spironolactone, finerenone does not cause gynaecomastia.

ESA Risks

Erythropoiesis-stimulating agents carry dose-dependent risks of hypertension (occurs in 20–30% — typically managed with antihypertensive adjustment), thromboembolic events, and when overused (targeting Hb >13 g/dL), increased risk of stroke and death (CHOIR, TREAT trials). Strict Hb target ceiling of 12 g/dL is essential.

Phosphate Binder and Active Vitamin D Risks

Calcium-based phosphate binders carry risk of hypercalcaemia and accelerated vascular calcification — use is now generally restricted to early-stage CKD without vascular calcification on imaging. Active vitamin D analogues (calcitriol, alfacalcidol) can cause hypercalcaemia and hyperphosphataemia at higher doses.

Avoiding Nephrotoxins

All CKD patients should be counselled to avoid NSAIDs (diclofenac, ibuprofen, naproxen) — even OTC preparations — as they reduce renal perfusion and are a leading cause of AKI on CKD. Aminoglycoside antibiotics (gentamicin, tobramycin) require serum level monitoring or preferably substitution. Contrast-induced AKI risk can be minimised by adequate pre-hydration and use of iso-osmolar contrast agents.

Systematic, structured monitoring is a cornerstone of CKD management. The frequency and scope of monitoring scales with CKD severity.

Blood Test Monitoring Frequency (KDIGO 2024)

• G1–G2: Annual eGFR, UACR, electrolytes (potassium, bicarbonate), blood pressure measurement
• G3a–G3b: Every 6 months — eGFR, UACR, potassium, bicarbonate, haemoglobin, serum phosphate, adjusted calcium, PTH (begin PTH monitoring at G3b), 25-hydroxyvitamin D
• G4: Every 3 months — all of the above plus Hb, iron studies (ferritin, transferrin saturation), urate, albumin. Begin RRT planning discussion.
• G5 (non-dialysis): Monthly or more frequent monitoring. Bicarbonate, fluid balance, uraemic symptom assessment at every visit.

Cardiovascular Risk Monitoring

12-lead ECG annually from G3b. Echocardiogram at nephrology referral to assess left ventricular hypertrophy and systolic/diastolic function. Fasting lipid profile and HbA1c annually in all CKD patients. Statin therapy is recommended for all CKD patients aged ≥50 (SHARP trial — simvastatin/ezetimibe reduced major atherosclerotic events by 17%).

AKI Sick Day Rules

All CKD patients should be provided with written 'sick day rules' instructing them to temporarily withhold ACEi/ARB, SGLT2 inhibitors, diuretics, and metformin during acute illness, vomiting, or diarrhoea to prevent AKI, and to rehydrate and restart medications only after recovery with GP/nephrologist guidance.

Preparation for Renal Replacement Therapy

From GFR ≤20 mL/min/1.73 m² or GFR 20–30 with rapid progression, preparation for RRT should be proactive: haemodialysis (arteriovenous fistula creation — at least 6 months before anticipated dialysis start), peritoneal dialysis (PD catheter insertion 3–6 weeks before start), or pre-emptive kidney transplant listing. Decision-making should be supported by a multidisciplinary team including nephrologist, transplant team, dietitian, social worker, and CKD nurse specialist.

The economic burden of CKD is substantial both to patients and healthcare systems. Understanding the cost landscape helps patients and families plan for long-term management.

Drug Costs

Generic ACE inhibitors and ARBs are now inexpensive globally — lisinopril 10 mg costs approximately INR 15–30 per month in India or USD 4–15 per month in the US on generic pharmacy programmes. SGLT2 inhibitors (dapagliflozin, empagliflozin) carry significantly higher costs — typically INR 2,500–4,500 per month in India and USD 250–450 per month in the US without insurance. Biosimilar and patent-expired versions are becoming available, expected to substantially reduce costs in 2025–2028. Finerenone (brand: Kerendia) costs approximately USD 450–550 per month in the US; significantly less in European and Asian markets. ESAs (darbepoetin alfa, epoetin alfa) for anaemia management cost USD 200–800 per month depending on dose and route.

Monitoring and Consultation Costs

Annual laboratory monitoring in India (eGFR, UACR, potassium, bicarbonate, FBC, iron studies, PTH, calcium, phosphate) typically costs INR 3,000–8,000 per year at private laboratories. Nephrology consultation fees range from INR 800 to INR 3,000 per visit at private hospitals. In the UK, CKD monitoring is generally covered by the NHS with no patient cost.

Hospitalisation Costs

AKI admissions cost USD 10,000–25,000 per episode in the US. Dialysis initiation hospitalisation costs INR 50,000–200,000 in India. The cost-effectiveness of preventive SGLT2 inhibitor therapy (preventing ESKD and cardiovascular hospitalisation) has been demonstrated in multiple health economic analyses in the US, UK, and India.

Government and Insurance Coverage

In India, SGLT2 inhibitors are included under some state government drug lists and are reimbursable under CGHS for CKD-diabetes. The Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (PMJAY) covers dialysis and some kidney transplant costs for eligible beneficiaries. Most private health insurance policies in India cover CKD complications, hospitalisation, and transplant after waiting periods, but may not cover routine outpatient drugs.

Beyond the established four-pillar approach, several emerging and complementary strategies are under investigation or increasingly used in CKD management.

Emerging Pharmacological Therapies

• Sparsentan (dual angiotensin-endothelin receptor antagonist): Approved in the US (2023) for IgA nephropathy. The PROTECT trial demonstrated significantly greater proteinuria reduction than irbesartan alone, with confirmatory 2-year data showing GFR preservation.
• Atrasentan: Endothelin receptor antagonist being evaluated in Phase III (ALIGN trial) for IgA nephropathy and diabetic kidney disease.
• Iptacopan: Complement factor B inhibitor approved (2023) for paroxysmal nocturnal haemoglobinuria-associated CKD; under investigation in C3 glomerulopathy.
• Potassium binders (patiromer, SZC): Enable continuation of RAAS blockade and finerenone in patients who would otherwise require dose reduction due to hyperkalaemia — increasingly seen as CKD-enablers rather than standalone treatments.
• HIF-PHI (roxadustat, daprodustat, vadadustat): Oral alternatives to injectable ESAs for CKD anaemia; approved in Japan, China, and several European markets.

Dietary and Lifestyle Approaches

• Low-protein diet (0.6–0.8 g/kg/day): Historically controversial, with some evidence of slowing GFR decline in non-dialysis CKD. Very-low-protein diets supplemented with keto-analogues (0.3–0.4 g/kg/day) may delay dialysis initiation in G4–G5.
• Sodium restriction (<2 g/day elemental sodium): Reduces blood pressure, proteinuria, and oedema — one of the most cost-effective CKD interventions.
• Mediterranean diet: Associated with slower CKD progression and reduced cardiovascular events in observational studies.
• Physical activity: Aerobic exercise 150 minutes per week is safe in most CKD stages and improves cardiovascular fitness, blood pressure, and quality of life.

Integrative and Complementary Medicine

Some CKD patients explore Ayurvedic formulations (e.g., Punarnava, Gokshura) or traditional Chinese medicine. Evidence for kidney-protective effects is limited to preclinical and small observational studies. Patients should be counselled that several herbal preparations (Ayurvedic heavy metals, Chinese herbs containing aristolochic acid) are directly nephrotoxic and should be avoided in CKD. All supplements should be disclosed to the treating nephrologist.